Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia). It may have continuous and/or episodic (paroxysmal) components.
DelveInsight’s “Neuropathic Pain Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Neuropathic Pain, historical and forecasted epidemiology as well as the Neuropathic Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Neuropathic Pain Report:
Request for Free Sample Report: https://www.delveinsight.com/sample-request/neuropathic-pain-market
Key benefits of the Neuropathic Pain report:
“It was observed that 67.5% of the patients with neuropathic pain were in the 65–74 age group.”
The primary goals of neuropathic pain treatment are to manage the pain as much as possible and to minimize the negative side-effects.
There are various neuropathic pain treatments available, and often it is a ‘trial and error’ process to find the best option for a person. Regular painkillers such as nonsteroidal anti-inflammatory drugs or NSAIDs (for example ibuprofen, aspirin and paracetamol) are usually not effective for neuropathic pain.
The key players in Neuropathic Pain market are:
Neuropathic Pain Drugs covered:
Table of contents
1. Report Introduction 2. Executive Summary 3. Neuropathic Pain Market Overview at a Glance 4. Neuropathic Pain Disease Background and Overview 5. Case Reports 6. Neuropathic Pain Epidemiology Methodology 7. Neuropathic Pain Epidemiology and Patient Population 8. Neuropathic Pain Country-Wise Epidemiology 9. Neuropathic Pain Treatments & Medical Practices 10. Neuropathic Pain Marketed Products 10.1. Tarlige: Daiichi Sankyo 11. Neuropathic Pain Emerging Therapies 11.1. Key Cross Competition 11.2. Mirogabalin/Tarlige: Daiichi Sankyo (For CNP) 11.3. Ricolinostat/HDAC6: Regenacy Pharmaceuticals 11.4. LAT8881: Lateral Pharma 12. Neuropathic Pain Market Size 13. 7MM Neuropathic Pain Country-Wise Market Analysis 14. Market Drivers 15. Market Barriers 16. SWOT Analysis 17. Reimbursement 18. Appendix 19. Neuropathic Pain Report Methodology 20. DelveInsight Capabilities 21. Disclaimer 22. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/neuropathic-pain-market
Related Reports:
Neuropathic Pain Pipeline
The Neuropathic Pain report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Neuropathic Pain across the complete product development cycle, including all clinical and nonclinical stages.
Neuropathic Pain Epidemiology
The Neuropathic Pain epidemiology covered in the report provides historical as well as forecasted Neuropathic Pain epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
About DelveInsight DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/neuropathic-pain-market